Mouwasat Medical Services Co.

Results Flash Note Q2-25



Highest quarterly top line delivered, yet upcoming expansion cost pressures likely limited bottom-line potential; in line with our estimates

Mouwasat reported a Q2-25 bottom line of SAR 187mn, up 22.4% Y/Y yet down 5.1% Q/Q, and in line with our forecasted SAR 189.3mn at a -1.2% deviation from our estimates. Record high quarterly top line of SAR 796mn drove this quarter's results, while revenue delivery to bottom line was limited by cost pressures which we expect are related to its upcoming expansions scheduled for H2-25. Top line for the quarter was likely driven by improved rejection rates and net price increases for its services, as well as patient volumes during a no-Ramadan-days Q2-24. Mouwasat's two expansions coming in will define the remainder of its FY25 performance, as it enters new geographies in a competitive market. We maintain our "Neutral" recommendation at a TP of SAR 86.4/share on the stock trading at a FY25E PE of 20.8x.

- Mouwasat reported a Q2-25 net income of SAR 187mn, up 22.4% Y/Y yet down 5.1% Q/Q. This was in line with our forecasted SAR 189.3mn at a -1.2% deviation from our estimates. Results were top line driven, as Mouwasat reported its highest quarterly revenues to date at SAR 796mn; likely driven by less rejection rates, price increases, and patient volumes. We expect that hirings for the upcoming facilities took place during the quarter to limit margin expansions on the GPM and operating margin front, and as OPEX-to-revenues also rose on a Y/Y and Q/Q basis to reach 19.2%. Decreases in impairment charges, finance charges, and zakat on a Y/Y basis further supported bottom-line performance.
- Quarterly revenues were reported at its highest recorded for Mouwasat at SAR 796mn, up 15.4% Y/Y and 4.2% Q/Q. Top line was in line with our estimated SAR 777mn at a +2.5% deviation. We consider the management's efforts to decrease rejection rates, as well as net price increases for services to have supported this quarter's top-line performance. Furthermore, no Ramadan days taking place this Q2-25, as well as potential increase in volume contribution from its Madina LTC facility opened early FY24 likely supported this quarter's revenue performance as well.
- Gross profit reached SAR 356mn, up 15.9% Y/Y and 2.7% Q/Q. This was in line with our estimated SAR 351mn at a +1.6% deviation. While quarterly revenues recorded their highest reported, gross profit did not follow suit, as GPMs remained locked lower than FY21-23 levels at near 44.8% (up 30bps Y/Y and down 40bps Q/Q). GPMs were reported slightly lower our estimates of 45.2% at a -40bps deviation. We expect that hiring activity potentially took place to weigh on GPMs, as management previously indicated that hirings are yet to take place for the upcoming two facilities scheduled for H2-25,
- Operating profits for the quarter reached SAR 203mn, up 15.5% and down 4.6% Q/Q. This was
 in line with our estimate of SAR 209mn at a -2.6% deviation. Operating margins, however, were
 flat Y/Y and down 250bps Q/Q, as OPEX-to-revenues reached 19.2% (up 20bps Y/Y and 170bps
 Q/Q) as a result of higher G&A costs likely related to the upcoming expansions.

AJC view and valuation: Mouwasat reported Q2-25 results in line with our estimated performance for the firm, as we expected the firm to deliver top-line performance driven by improved contractual terms, along with cost pressures related to upcoming expansions. The two facilities around the corner (Yanbu at 200 beds, and Jeddah at 300 beds, both by H2-25E) are expected to define the performance of Mouwasat for the remainder of the year. We remain cautious on increasing competitive pressures on patient attraction and talent hirings, particularly in Jeddah, which is a new geography for Mouwasat. We expect Mouwasat to be on track to deliver a FY25E bottom line of SAR 741mn driven by its expansions, at a FY25E forward PE of 20.8x, and an expected dividend of SAR 2.25 per share at a 2.6% dividend yield. We maintain our TP on the firm at SAR 86.4/Share at a "Neutral" recommendation.

Results Summary

•						
SAR mn	Q2-24	Q1-25	Q2-25	Change Y/Y	Change Q/Q	Deviation from AJC Estimates
Revenue	690	764	796	15.4%	4.2%	2.5%
Gross Profit	307	347	356	15.9%	2.7%	1.6%
Gross Margin	44.5%	45.4%	44.8%	-	-	-
EBIT	176.2	213	203	15.5%	-4.6%	-2.6%
Net Profit	152.7	197	187	22.4%	-5.1%	-1.2%
EPS	0.76	0.99	0.93	_	-	-

Source: Company Reports, AlJazira Capital Research

Recommendation	Neutral
Target Price (SAR)	86.4
Upside / (Downside)*	12.4%

Source: Tadawul *prices as of 29th of July 2025

Key Financials

SARmn (unless specified)	FY22	FY23	FY24	FY25E
Revenues	2,334	2,706	2,879	3,177
Growth %	8.9%	15.9%	6.4%	10.3%
Gross profit	1,102	1,313	1,289	1,377
Growth %	10.6%	19.2%	-1.8%	6.8%
Oper. Income	672	757	724	837
Growth %	8.1%	12.6%	-4.3%	15.5%
Net Income	599.3	657.7	646	741
Growth %	3.7%	9.7%	-1.8%	14.8%
EPS	3.00	3.29	3.23	3.71
DPS	1.50	1.75	2.00	2.25

Source: Company reports, Aljazira Capital Research

Key Ratios

	FY22	FY23	FY24	FY25E
Gross Margin	47.1%	48.5%	44.8%	43.3%
Oper. Margin	28.8%	28.0%	25.2%	26.3%
Net Margin	25.7%	24.3%	22.4%	23.3%
ROA	13.7%	13.7%	12.5%	13.3%
ROE	21.7%	21.2%	18.9%	19.9%
P/E (x)	69.7	34.0	26.4	20.8
P/B (x)	7.2	6.8	4.8	4.0
Dividend Yield	0.7%	1.3%	2.1%	2.6%

Source: Company reports, Aljazira Capita Research

Key Market Data

Market Cap(bn)	15.4
YTD%	-9.6%
52 week (High)/(Low)	122.4/65.6
Share Outstanding (mn)	200

Source: Company reports, Aljazira Capital Research

Price Performance



Source: Tadwaul, Aljazira Capital Research

Senior Equity Analyst

Ibrahim Elaiwat

+966 11 2256115

i.elaiwat@Aljaziracapital.com.sa



Head of Sell-Side Research - Director Jassim Al-Jubran +966 11 2256248 j.aljabran@aljaziracapital.com.sa

RESEARCH

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

FERMINOLOGY RATING

- Overweight: This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
- Underweight: This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve
- Neutral: The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve
- Suspension of rating or rating on hold (SR/RH): This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. Aljazira Capital, its employees, one or more of its affiliates, or its clients may have investments in the securities or assets referred to in this report. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or thirdparty persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Investment Banking | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia, Tel: 011 2256000 - Fax: 011 2256068